Dispatch
Insights for revenue cycle leaders
RCM trends, denial analysis, and operational strategy from the Exactrx team.
Hospitals spent $18B fighting denials in 2025. AR days rose 5.2% anyway. Here's what the data says about why, and what to do.
The IDR admin fee drops 85% to $15 in August 2026. Here's how batching rules and a new registry reshape your dispute economics.
When 97% of appealed denials get overturned, the initial denial stops being clinical. Here's what that means for your RCM strategy.
Denial management is now one of the costliest jobs in the revenue cycle. The groups pulling ahead score claims for denial risk before they ever reach the payer.
A veteran ASC operator shares hard-won lessons on RCM timing, credentialing pitfalls, and where AI actually helps in ambulatory surgery centers.
CMS projects 2.3M Medicaid enrollees lost by FY2027. Here's what that shift means for ASC and outpatient payer mix.
CMS's 2026 skin substitute reclassification cuts $19.6B in Medicare spending. Here's what wound care and surgical leaders must do now.
Merritt Healthcare's Danilo D'Aprile on succession, margin, and why the smartest people in healthcare run surgery centers, and no one's listening.
CMS is expanding prior authorization while pulling back transparency rules. Here's what revenue cycle leaders must do before denials compound.
41% of providers absorb $5M+ in annual denial write-offs. Here's what RCM leaders must do before the losses compound further.